Staphefekt: sustainable antibacterial therapy with endolysins
Please note that for mobiles we stream the presentation slides and audio of the speaker.
This video has been archived as it is more than 2 years old. CPD is no longer available.
Mark Offerhaus and Bjorn Herpers give a talk on the development of Staphefekt - a new antibacterial technology for the treatment of infectious skin conditions (Staph. aureus). Staphefekt is completely independent of antibiotics and is based on the use of endolysins.
Bjorn Herpers talks through some patient cases, showing Staphefekt's success in the treatment of ezcema, rosacea, furunculosis and more. Micreos hope to set a new standard of treatment that will replace antibiotics, and have made Staphefekt free to use for research purposes.
This lecture was part of the 'Medical Innovations Summit 2015' at The Royal Society of Medicine in London.
Date of lecture: 18th April 2015
This video is available for iPad via Safari